Celebrating Innovation: Georgia Bio Summit 2024 Company Showcase Winners

Celebrating Innovation: Georgia Bio Summit 2024 Company Showcase Winners

The Georgia Bio Summit 2024 was a remarkable gathering of life sciences leaders, innovators, and changemakers. This year’s Company Showcase featured 10 groundbreaking companies, all showcasing the cutting-edge innovation happening right here in Georgia and beyond. The level of competition was truly exceptional, and we are excited to announce the Top 3 Winners of the 2024 Showcase Summit:



1st Place: OrthoPreserve

OrthoPreserve impressed the judges with its innovative solutions in regenerative medicine and tissue preservation, paving the way for advancements in orthopedic care. Their work is not only transforming how we approach patient recovery but also demonstrating the impact of cutting-edge research in improving outcomes.


2nd Place: JellyCo USA

JellyCo USA stood out with its groundbreaking advancements in marine biomaterials. Their work is leading the charge in sustainable and scalable solutions for various applications, creating a meaningful impact on the future of life sciences.


3rd Place: NeurOp

NeurOp continues to push boundaries in neurological drug development, addressing unmet needs for patients with brain and nervous system disorders. Their innovation reflects a deep commitment to improving lives through science and discovery.


Honoring All Participants

While we celebrate our winners, we want to shine a spotlight on the other incredible companies that were part of this year’s showcase. These organizations exemplify the innovative spirit driving life sciences forward:

  • Atomistic Insights
  • Autofrax
  • Lena Biosciences
  • ARNAV Biotech
  • Intelligent Dots
  • Annoviant
  • OncoSpherix


Your dedication to advancing health and science inspires us all. Each of you contributes to making Georgia a hub for life sciences innovation, and we are honored to have you as part of our community.


A Bright Future for Georgia Life Sciences

This year’s Company Showcase proved that the future of life sciences in Georgia is brighter than ever. The level of talent, innovation, and collaboration on display underscores the importance of fostering a thriving ecosystem for startups and established companies alike.

As we look ahead, Georgia Bio remains committed to supporting these companies through programs, partnerships, and initiatives that drive growth and opportunity in the life sciences sector. Together, we’re not just building businesses – we’re improving lives and creating a healthier tomorrow.


Congratulations again to all participants and especially to our winners, OrthoPreserve, JellyCo USA, and NeurOp. We can’t wait to see the incredible advancements you’ll achieve in the coming years.


#GeorgiaBioSummit #LifeSciences #Innovation #Entrepreneurship #CompanyShowcase2024

March 24, 2026
Georgia Life Sciences is thrilled to be featured in the very first Atlanta edition of Inside Medicine . This inaugural issue represents something truly special. Atlanta’s healthcare and life sciences community is driven by innovation, collaboration, and outstanding leadership—and we’re honored to be part of this exciting launch. Also in the issue, GLS's Kennedy Dumas is featured, sharing her journey on how observation and research evolved into a powerful practice of journaling. As the founder of Stationery Black, she creates notebooks designed to showcase, uplift, and inspire people of color. Read the full article here.
March 24, 2026
A new national outlook on the life sciences real estate market is reinforcing what many in Georgia’s ecosystem have been building toward: a more disciplined, workforce-driven, and manufacturing-focused future for the industry. CBRE’s 2026 U.S. Life Sciences Market Outlook points to a sector in transition—moving away from rapid, speculative expansion toward a more measured phase defined by targeted growth, capital efficiency, and long-term sustainability. For Georgia, these trends are not just informative—they are validating. A Market Reset Creates Opportunity After several years of rapid expansion in major coastal markets, the national lab space market is recalibrating. Construction has slowed significantly, and vacancy rates—while still elevated—are stabilizing. This shift favors emerging markets like Georgia that have taken a more measured approach to growth. Rather than contending with oversupply, Georgia is well-positioned to scale intentionally—aligning infrastructure, workforce, and industry demand in a way that supports long-term success. Manufacturing and Scale-Up Are Driving Growth One of the clearest signals from the CBRE report is the increasing role of large pharmaceutical and biomanufacturing investments in driving demand. This aligns directly with Georgia’s recent momentum. From major facility expansions to increased interest in onshoring and domestic production, the Southeast—and Georgia in particular—is becoming a destination for advanced manufacturing in the life sciences. The Georgia Life Sciences Roadmap has consistently emphasized this opportunity: Strengthening biomanufacturing capacity Building workforce pipelines to support production scale Positioning Georgia as a hub for both innovation and commercialization Workforce as the Differentiator As capital becomes more selective and companies prioritize execution, talent—not space—is emerging as the defining constraint. Georgia’s investments in workforce development, including partnerships with the Technical College System of Georgia and the Georgia Bioscience Training Center, position the state to meet this moment. Through coordinated efforts across education, industry, and government, Georgia is building the kind of workforce infrastructure that enables companies to not only locate here—but to grow here. A Converging Ecosystem Another key trend highlighted in the report is the convergence of life sciences with adjacent sectors such as digital health, robotics, and advanced technologies. This is an area where Atlanta stands out. With strengths in medtech, health IT, and data-driven healthcare solutions, the region offers a broader definition of “life sciences”—one that reflects where the industry is headed, not where it has been. Looking Ahead The national life sciences sector is entering a new phase—one that rewards strategic alignment, ecosystem coordination, and long-term investment. Georgia is not starting from scratch in this environment. It has been building toward it. The Georgia Life Sciences Roadmap anticipated many of these shifts, prioritizing: Workforce development Manufacturing and scale-up capacity Industry-academic collaboration Capital and commercialization pathways As national trends continue to evolve, Georgia’s focus on disciplined, intentional growth positions the state—and the broader Southeast—as a compelling partner in the next chapter of the life sciences industry.  Read report - CBRE Chapter 9, Life Sciences - U.S. Real Estate Market Outlook 2026 https://www.cbre.com/insights/books/us-real-estate-market-outlook-2026/life-sciences
March 24, 2026
B y Trevor Williams , March 24, 2026 | Global Atlanta More than 60 Belgian firms have found a home in Georgia, but nothing on this scale has yet been seen in the state. The amalgam of Belgian investment, carried out over a half-century, translates to about 5,000 current jobs. Gwinnett offered $174 million in incentives to win the project, including property tax abatements, fee waivers and utility improvements, according to Rowen. UCB is set to bring in artificial intelligence, advanced robotics and automation at the site. Biologics are therapies made from living organisms, promising cutting-edge research and manufacturing. Maria Thacker Goethe , president and CEO of Georgia Life Sciences , said the move gives state leaders even more impetus to work collaboratively to build Georgia’s talent pipeline “across every stage — from high school exposure and technical credentials to community college, university, and incumbent-worker upskilling.” “UCB’s decision underscores the strength of Georgia’s talent base, manufacturing capacity, and collaborative business climate, and it reflects the kind of long-term investment that helps build a more resilient U.S. biomanufacturing footprint,” Ms. Goethe told Global Atlanta in an email. Nine of the 16 FDA approvals for UCB drugs and therapies have come within the last three years, showing its prioritization of the U.S. market, where headcount has grown 73 percent since 2017 to 2,000 people. UCB’s products treat severe neurological and immunological conditions like epilepsy, lupus, Parkinson’s disease, rheumatoid arthritis and many more. Read the full article here: UCB Sticks With Georgia, Placing $2 Billion Bet on State’s Life Sciences Ecosystem - Global Atlanta
MORE POSTS